GLP-1
In response to the global health emergency caused by the recent outbreak of coronavirus strain 2019-nCoV, LGC’s SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostic manufacturers and clinical laboratories, is announcing the development of molecular reference materials for coronavirus utilizing their proprietary AccuPlex™ recombinant technology.
Arbor Biosciences announced a partnership with Biosearch Technologies, the complete genomics portfolio of LGC Group.
Global reach extended to major pharma market in Oceania
Novo Nordisk specializes in the diabetes market. The company appears to be making an entry into the Alzheimer’s market, which isn’t as unusual or unexpected as it initially sounds.
For patients with diabetes, the new indication could become a key for survival as there is a well-established link between cardiovascular disease and type 2 diabetes.
NBE-Therapeutics AG announces the closing of a USD 22M Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all private shareholders.
Antabio’s Pseudomonas Elastase Inhibitor (PEi) has the potential to significantly enhance the effectiveness of current CF therapy
With a new year upon us, some analysts are already picking potential winners in the market for 2020. One of those companies could be Denmark-based Novo Nordisk.
Looking back over the past year and even decade, STAT News takes a look back at the best drugs approved over the past 10 years in its weekly Readout podcast.
Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of approved proteins, announced its financial calendar for 2020.
PRESS RELEASES